If they haven’t already, health plans will soon see a rapid rise in the number of members and providers asking whether genomic testing is covered and to what degree. Even though genomic testing may be a small part of a health plan’s benefit management program it can represent a meaningful portion of the risk. And a risk that will only increase if the health plan does not have a well-designed genomics benefit management (GBM) plan in place.
by InformedDNA Understand the Value and Expertise Your Genomic Benefits Manager Can Provide Health plans are increasingly looking towards outside benefit managers for support with genomic benefits management. But how do you know that a benefits manager may meet your unique needs and the demands of the genomic testing landscape? We’ve prepared 10 questions for …
Executive Summary, by InformedDNA Precision medicine that harnesses advances in genomics holds enormous promise for impacting every aspect of a health plan’s business. When properly integrated, genomics enables more tailored care with the potential for tremendously improved outcomes–especially in specialties such as oncology and reproductive health. Genomics is a technically complex discipline with a growing …
Achieving Value through Comprehensive Genomic Benefits Management (GBM) Read More »
A guide to navigating the challenges that come with developing and implementing clinical trials for genetic diseases Despite significant progress, incorporating genetic data into clinical trials still presents a great deal of challenges for sponsors and CROs, especially as they struggle with the added concerns of patient identification and enrollment, guidelines around use of genetic …
Inappropriate genetic test claims are often mistakenly paid because claims systems can’t identify the actual test(s) performed and apply correct policy. In fact, research shows that 30 percent of genetic testing claims are coded inaccurately. Other factors that contribute to higher-than-necessary costs for genetic testing include lack of medical necessity, volume billing, and widely variant …
Webinar: A Proven Payment Integrity Solution for Genetic Testing Claims Read More »
Our client, a leading biotech innovator committed to developing revolutionary personalized therapies for dementia and Alzheimer’s disease patients, relies heavily on positive outcomes from its clinical trials. Yet, identifying appropriate patients with the right gene mutation for these trials can be a challenge. When trial sites failed to identify enough patients for a phase 3 …
Genomics is a technically complex discipline with a growing number of expensive tests and treatments. However, rapid advances in genomics currently far outpace the resources that most health plans are able to allocate to keep up with the developments. Although genomics now informs diagnoses and treatments that often cross medical specialties, plans are challenged to …
Rapid advances in genomic science and the implementation of personalized medicine require new approaches to health plan policy and evidence review processes. InformedDNA genetics experts have developed a forward-thinking approach with its Coverage Decision Framework™, enabling health plans to develop timely policies that ensure members have access to the most current, effective and safe approaches …
Patient enrollment can be difficult for clinical trials targeting rare genetic diseases. These trials typically target very small patient populations, leading to challenges in enrolling patients. Also, enrollment is often restricted by logistical and social barriers such as language, participants’ ability to take time off from work, and participants’ ability to travel to research sites. …
Whitepaper: Patient Diversity in Rare Disease Clinical Trials Read More »
Patient populations affected with orphan diseases are rare and patient identification can be challenging and time-consuming. Our pharmaceutical client, while anticipating likely FDA approval for its new gene therapy, faced significant challenges identifying affected patients and encouraging the adoption of genetic testing into community physician practices. Learn how the InformedACCESSTM solution we deployed with our client resulted …
Case Study: Post-Market Success for a New Gene Therapy Read More »
Copyright ©2023 InformedDNA® All Rights Reserved